Neuron23

Neuron23 is a clinical-stage precision-medicine biotechnology company developing genetically targeted small-molecule therapies for neurological and immunological diseases, with a lead precision-medicine program focused on Parkinson's disease. It combines machine-learning-driven genetic biomarker discovery with drug development to match patients to the therapies most likely to help them. Surfaced in the API Evangelist network as a portfolio company of SoftBank Vision Fund, Neuron23 is a therapeutics company that publishes no public API, developer portal, SDK, or technical documentation surface as of this enrichment pass.

Neuron23 is profiled on the APIs.io network. Tagged areas include Company, Health Tech, Biotechnology, Precision Medicine, and Neuroscience.

Neuron23’s developer surface includes product news and 3 more developer resources.

6.8/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-07-27 · rubric v0.5
0 APIs
CompanyHealth TechBiotechnologyPrecision MedicineNeurosciencePharmaceuticalsDrug DiscoveryParkinsons Disease

Kin Score

Kin Score Kin Score How this is scored →
scored 2026-07-27 · rubric v0.5
Composite quality — 6.8/100 · minimal
Contract Quality 0.0 / 25
Developer Ergonomics 0.0 / 20
Commercial Clarity 0.0 / 20
Operational Transparency 0.0 / 13
Governance 0.0 / 12
Discoverability 6.8 / 10
Agent readiness — 0/100 · human only
Machine-Readable Contract 0 / 18
Agentic Access Contract 0 / 15
MCP Server 0 / 12
Machine-Readable Auth 0 / 10
Idempotency 0 / 9
Stable Error Semantics 0 / 8
Request/Response Examples 0 / 7
Rate-Limit Signaling 0 / 7
Typed Event Surface 0 / 6
Agent Skills 0 / 5
Well-Known Catalog 0 / 4
Consent & Bot Identity 0 / 3
Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/neuron23: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Security Posture 1

Authentication, domain security, vulnerability disclosure, and trust-center signals.

Neuron23 Domain Security

TLSv1.3 · HSTS

SECURITY

Resources

Access & Security 1

Authentication, authorization, and security posture

Company 3

The organization behind the API

Source (apis.yml)

apis.yml Raw ↑
aid: neuron23
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/neuron23.png
name: Neuron23
description: Neuron23 is a clinical-stage precision-medicine biotechnology company developing genetically targeted small-molecule
  therapies for neurological and immunological diseases, with a lead precision-medicine program focused on Parkinson's disease.
  It combines machine-learning-driven genetic biomarker discovery with drug development to match patients to the therapies
  most likely to help them. Surfaced in the API Evangelist network as a portfolio company of SoftBank Vision Fund, Neuron23
  is a therapeutics company that publishes no public API, developer portal, SDK, or technical documentation surface as of
  this enrichment pass.
url: https://raw.githubusercontent.com/api-evangelist/neuron23/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- softbank-vision-fund
x-tier: stub
x-tier-reason: portfolio-lead
specificationVersion: '0.20'
created: '2026-07-17'
modified: '2026-07-20'
tags:
- Company
- Health Tech
- Biotechnology
- Precision Medicine
- Neuroscience
- Pharmaceuticals
- Drug Discovery
- Parkinsons Disease
apis: []
common:
- type: Website
  url: https://neuron23.com/
- type: About
  url: https://neuron23.com/about
- type: News
  url: https://neuron23.com/news
- type: DomainSecurity
  url: security/neuron23-domain-security.yml
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
x-enrichment:
  date: '2026-07-20'
  status: minimal
  artifacts_added: 1
  pass: local-v1